George A. Robertson

发表

Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell Vaccine

R. Malley, C. Thompson, P. Anderson, 2010, Clinical and Vaccine Immunology.

Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine.

S. Joshi, D. Volkin, Lei Hu, 2013, Journal of pharmaceutical sciences.

Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability.

R. Malley, P. Anderson, L. Leite, 2014, Vaccine.

GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.

S. Sayeed, R. Malley, C. Thompson, 2010, Vaccine.

Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.

A. Fix, S. Cryz, L. Dally, 2015, Vaccine.

Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine

S. Joshi, D. Volkin, R. Sitrin, 2020, Journal of pharmaceutical sciences.

Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens

S. Joshi, D. Volkin, R. Sitrin, 2019, Journal of pharmaceutical sciences.

Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant

S. Joshi, D. Volkin, J. Hickey, 2017, Vaccine.

Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant

S. Joshi, D. Volkin, J. Hickey, 2017, Journal of pharmaceutical sciences.